Screener
TransMedics Group, Inc. TMDX Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206453
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of revenue: | ||
| Cost of net product revenue | 24,308 | 16,312 |
| Cost of service revenue | 48,464 | 38,997 |
| Total cost of revenue | 72,772 | 55,309 |
| Gross profit | 101,161 | 88,228 |
| Operating expenses: | ||
| Research, development and clinical trials | 24,879 | 17,160 |
| Selling, general and administrative | 62,985 | 43,625 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is TransMedics Group, Inc.'s total cost of revenue?
- TransMedics Group, Inc. (TMDX) reported total cost of revenue of $72.77M in Q1 2026.
- How has TransMedics Group, Inc.'s total cost of revenue changed year-over-year?
- TransMedics Group, Inc.'s total cost of revenue increased by 31.6% year-over-year, from $55.31M to $72.77M.
- What is the long-term trend for TransMedics Group, Inc.'s total cost of revenue?
- Over 4 years (2021 to 2025), TransMedics Group, Inc.'s total cost of revenue has grown at a 127.2% compound annual growth rate (CAGR), from $9.1M to $242.69M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about TransMedics Group, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude